Diabetes News April 30th 2010

Calling all people with Type 2 diabetes and healthcare professionals
Diabetes UK would like you to fill in a quick and easy online survey about hypoglycaemia or ‘hypos’(Diabetes UK)

Relationship of baseline HBA1c and efficacy of glucose lowering therapies
A meta-analysis of randomised clinical trials (NHS Evidence – Diabetes )

Type 2 Diabetes Prevention: A Review
Recent clinical trials have convincingly shown that lifestyle modification is the most effective tool in the prevention or delay of type 2 diabetes (Clinical Diabetes)

Incorporating Type 1 Diabetes Prevention Into Clinical Practice
Successful intervention efforts demand a thorough understanding of disease pathogenesis and a refined approach to disease prediction so that risks and benefits can be well balanced (Clinical Diabetes)

Etiology of Type 1 Diabetes
This review considers research in the field of type 1 diabetes toward identifying disease mechanisms using genetic approaches (Immunity)

Advances in the Treatment of Diabetic Retinopathy
Diabetic retinopathy is the most common microvascular complication of diabetes and remains one of the leading causes of blindness worldwide among adults aged 20-74 years (Discovery Medicine)

Comparative-Effectiveness Study Confirms New Treatment for Diabetic Macular Edema
Researchers have shown that ranibizumab (Lucentis) eye injections, often in combination with laser treatment, result in better vision than laser treatment alone for diabetes-associated swelling of the retina (NIH News)

IVGTT glucose minimal model covariate selection by nonlinear mixed-effects approach
In this work, the advantages of population techniques are further explored by proposing integration of covariates in the intravenous glucose tolerance test (IVGTT) glucose minimal model analysis (American Journal of Physiology – Endocrinology and Metabolism)

Victoza is a “better diabetes drug”
Both high and low-dose injections of new diabetes drug Victoza are more effective at reducing blood-sugar levels than a daily dose of Januvia, researchers in the US have claimed (Pharmacy Europe)

Phenomix Announces Positive Results from a Phase 3 Study of Dutogliptin in Type 2 Diabetes Mellitus
Dutogliptin is Phenomix’ internally-discovered dipeptidyl peptidase-4 (DPP-4) inhibitor (PharmaLive)